NSI Logo

Evolving Innovative Solutions™ - Since 1993



Natural Selection, Inc. has unique expertise in the application of a diverse range of computational intelligence methods applied to problems in medicine. Using our Connect® software tools, we are committed to designing exceptional software that can assist in your biomedical/cheminformatics needs. Natural Selection, Inc. has experience in the following areas:

Examples of our recent successes:


microRNA Discovery and Analysis

Under SBIR funding by the National Science Foundation, Natural Selection, Inc. develop evolved classifiers to predict the locations of microRNA genes in genomic DNA. These predictions led to many novel microRNA sequences that were later confirmed by experimental analysis and deep sequencing. A portion of this data was licensed for commercial sale by Invitrogen (now Life Technologies) for sale on the NCode™ Multi-species miRNA Microarray. This microarray is currently being used by researchers world-wide for the investigation of small RNA expression in various tissues, leading to a better understanding of cellular development. Natural Selection, Inc. is currently working on projects involving microRNA expression in HIV and cellular differentiation.



Through a collaboration with BioInfoExperts and UC San Francisco under funding from the National Institutes of Health, Natural Selection, Inc. helped co-develop classifiers for to predict viral tropism as well as classifiers for late-stage pathogenic effects of HIV infection including risk of dementia and lymphoma. The team continues to explore the biology of HIV-related dynamics, signatures, and structures associated with the development of AIDS-related pathogenicity.


High-throughput Drug Screening

Through a collaboration with Southwestern College under funding from the U.S. Army, Natural Selection, Inc. helped develop a novel approach for high-throughput small molecule screening that makes use of computational intelligence methods to literally evolve drugs in silico and screen drugs against protein targets. This process rapidly accelerates the search for new drug compounds over standard laboratory techniques and has been evaluated for its use in anti-malarial drug discovery.

For additional information on Natural Selection, Inc.'s efforts in medicine, please review our publications or contact Dr. Gary Fogel, CEO at gfogel [at] natural-selection.com.